Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 1315,74 € (+2,97 %). La mediana es de 1313,51 € (+2,79 %).
| Comprar |
34 |
| Mantener |
9 |
| Vender |
3 |
Debates en la comunidad
Traducido del alemán
Vender o mantener NovoHola a todos, todavía estoy dudando si debo vender mi posición en Novo y reorientar el dinero hacia mis ETFs (All World/High Dividenden). Compré el título hace un tiempo, en aquel momento no conocía…
D Denny II en Portfolio Roasts
6 35
Noticias Ir al feed de noticias
Eli Lilly to acquire Calytrix Bio for up to $1.5 billion to broaden portfolio beyond obesity
Eli Lilly agreed to buy privately held Calytrix Bio for up to $1.5 billion to obtain an early-stage antibody therapy for rare blood disorders, part of Lilly’s strategy to deploy GLP-1 windfall proceeds to diversify beyond its obesity franchise. The deal is small in near-term impact but consistent with an accelerated M&A cadence under CEO David Ricks. Barclays raised its Lilly price target after the company’s strong Q3 results and highlighted Lilly’s Dec. 7 innovation day as another catalyst. » Más en cnbc.com
Eli Lilly gets approval in China for oral GLP-1 therapy orforglipron
Eli Lilly has received China's first approval for an oral GLP-1 active ingredient for weight loss, orforglipron, securing a strategic lead in the world's second-largest pharmaceutical market. The tablet form substantially expands the addressable patient pool versus injectable preparations and is likely to add revenue to the obesity business. Analysts see billion-dollar market potential in China, while Lilly’s pipeline, including retatrutide and other candidates, offers additional growth sources. The combination of market access, a strong obesity business and a broad pipeline supports the stock's current upward trend. » Más en deraktionaer.de
Eli Lilly's Foundayo cuts severity of obstructive sleep apnea in late-stage trial, company to seek FDA approval
Foundayo significantly reduced apnea-hypopnea index (AHI) and hypoxic burden versus placebo in two late-stage studies of adults with obesity or overweight, with non-PAP patients seeing an average reduction of 21.1 AHI events per hour versus 4.8 for placebo and a 43.8% overall AHI decrease. Lilly plans to file for U.S. approval by year-end for a daily pill to treat moderate-to-severe obstructive sleep apnea. The drug also produced roughly 11% average weight loss at 52 weeks and lowered an inflammation marker; common side effects were gastrointestinal and led to higher discontinuation rates versus placebo. » Más en cnbc.com
Eli Lilly raises outlook — pipeline candidates could deliver next growth wave
Eli Lilly surprised with strong quarterly results and raised its full-year guidance. Growth is currently being driven by Mounjaro and Zepbound, while Retatrutide, Foundayo and EloraTZP are advancing in clinical trials and could provide substantial additional revenue if approved. The company is also expanding production capacity in Texas and Virginia to meet demand. The pipeline’s progress and recently released data support the outlook for continued growth. » Más en deraktionaer.de
Eli Lilly in focus: quarterly report decides valuation premium for healthcare stocks
Healthcare stocks have strongly recovered since April and are now trading at higher valuations than the broader market, after the sector traded at about a 25% discount a year ago. The rotation is seen mainly as a contrarian bet against the AI boom, with investors pulling money from tech ETFs into pharma and medical names; Johnson & Johnson and Eli Lilly account for a large share of the premium. Whether the higher valuation holds depends, analysts say, on whether medical innovation builds confidence, political risks remain muted, and large companies like Eli Lilly meet high expectations in their quarterly results. Today's quarterly report and Eli Lilly's conference call are seen as a key test of the sustainability of the healthcare rally. » Más en finanzen.net
Dividendos históricos Dividendos
Todas las métricas de dividendos Todas las métricasDatos financieros de la empresa
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 21,54 mil M | 43,61 % |
| Beneficio bruto | 18,07 mil M | 45,29 % |
| Beneficio neto | 5695,27 M | 19,72 % |
| EBITDA | 8236,11 M | 22,62 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 1,24 B € |
Número de acciones | 940,75 M |
Máximo/mínimo de 52 semanas | 1331,75 € - 775,80 € |
Rentabilidad por dividendo | 0,44 % |
Dividendos TTM | 5,76 € |
Próximo dividendo | 1,57 € |
Beta | 0,45 |
Ratio P/E | 46,73 |
Ratio PEG | 0,92 |
Ratio P/B | 31,97 |
Ratio P/S | 15,71 |
Perfil de la empresa
Eli Lilly and Company descubre, desarrolla y comercializa medicamentos de uso humano en todo el mundo. Ofrece Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulina lispro, insulina lispro protamina, insulina lispro mezcla 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R y Humulin U-500 para la diabetes; y Jardiance, Trajenta y Trulicity para la diabetes tipo 2. La compañía proporciona Alimta para el cáncer de pulmón de células no pequeñas (NSCLC) y el mesotelioma pleural maligno; Cyramza para el cáncer gástrico metastásico, el adenocarcinoma de la unión gastroesofágica, el NSCLC metastásico, el cáncer colorrectal metastásico y el carcinoma hepatocelular; Erbitux para los cánceres colorrectales y diversos cánceres de cabeza y cuello; Retevmo para el NSCLC metastásico, el carcinoma medular de tiroides y el cáncer de tiroides; Tyvyt para el linfoma de Hodgkin clásico recidivante o refractario y el NSCLC no escamoso; y Verzenio para el cáncer de mama metastásico HR+, HER2-, el cáncer de mama con ganglios positivos y el cáncer de mama temprano. Ofrece Olumiant para la artritis reumatoide; y Taltz para la psoriasis en placas, la artritis psoriásica, la espondilitis anquilosante y la espondiloartritis axial no radiográfica. La compañía ofrece Cymbalta para el trastorno depresivo, el dolor neuropático periférico diabético, el trastorno de ansiedad generalizada, la fibromialgia y el dolor musculoesquelético crónico; Emgality para la prevención de la migraña y la cefalea en racimos episódica; y Zyprexa para la esquizofrenia, el trastorno bipolar I y el mantenimiento del trastorno bipolar. Sus anticuerpos Bamlanivimab y etesevimab, y Bebtelovimab para la COVID-19; Cialis para la disfunción eréctil y la hiperplasia prostática benigna; y Forteo para la osteoporosis. La compañía tiene colaboraciones con Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; y Foghorn Therapeutics Inc. Eli Lilly and Company se fundó en 1876 y tiene su sede en Indianápolis, Indiana.
| Nombre | Eli Lilly & Co |
| CEO | David A. Ricks |
| Sede | Indianapolis,
in Estados Unidos |
| Sitio web | |
| Sector | Salud |
| Industria | Productos farmacéuticos |
| Salida a bolsa | 01/06/1972 |
| Empleados | 50.000 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NYSE | LLY |
XETRA | LLY.DE |
SIX | LLY.SW |
Frankfurt | LLY.F |
Düsseldorf | LLY.DU |
Hamburg | LLY.HM |
Milan | 1LLY.MI |
London | 0Q1G.L |
München | LLY.MU |
Wien | LLYC.VI |